FDA Approves Breztri as First Triple Therapy Inhaler for Asthma

On April 28, 2026, AstraZeneca's fixed-dose triple-combination inhaler Breztri Aerosphere received FDA approval for the maintenance treatment of asthma in adults and pediatric patients aged 12 and older.1 The approval marks the product's second approved indication after its 2020 clearance for chronic obstructive pulmonary disease in adults. The approval makes Breztri the only single-inhaler triple therapy available for asthma in the US.

Breztri combines budesonide, glycopyrrolate, and formoterol fumarate delivered via the Aerosphere pressurized metered-dose inhaler.1 The platform required solving non-trivial particle engineering and suspension stability challenges to co-formulate 3 active substances with distinct physicochemical properties. The COPD formulation, approved at a slightly different dose (320/18/9.6μg), has been prescribed to more than 6.8 million patients globally as of 2025, providing a substantial real-world dataset on the inhaler's performance and patient handling.

What Did the Clinical Program Demonstrate, and Why Does it Matter for Development Teams?

The approval was based on the Phase III KALOS and LOGOS trials, replicate confirmatory, randomized, double-blind studies enrolling approximately 4,300 patients across 24-to-52-week variable-length treatment periods.1 The trials compared Breztri against dual-combination corticosteroid/long-acting beta2-agonist therapy, both a marketed reference product (Symbicort) and a formulation-matched comparator (budesonide/formoterol fumarate in the same Aerosphere device), allowing regulators to isolate the contribution of the added long-acting muscarinic antagonist component.

The primary endpoint in the US regulatory submission was change from baseline in forced expiratory volume in 1 second area under the curve from 0 to 3 hours at week 24, with trough forced expiratory volume at week 24 as the key secondary endpoint.1 Results published in The Lancet Respiratory Medicine in February 2026 showed statistically significant and clinically meaningful improvements in lung function versus the dual-therapy comparators. A secondary finding was a measurable improvement in lung function within five minutes of the first dose. No new safety or tolerability signals were identified relative to the established COPD profile/

Njira Lugogo, MD, clinical professor in the Division of Pulmonary and Critical Care Medicine, the University of Michigan, describes in a press release,1 "Despite the availability of dual maintenance therapy, many patients are still at risk for exacerbations and experience daily breathing difficulties, reduced lung function and the ongoing fear of worsening symptoms. The FDA approval of Breztri as the only maintenance triple therapy for people with asthma 12 years of age and older marks a pivotal moment in helping those living with this debilitating disease breathe better, sooner."

What Are the Implications for the Broader Respiratory Pipeline?

Asthma affects an estimated 262 million people worldwide, including 27 million in the US, and approximately half of those patients remain inadequately controlled on dual therapy.1 The unmet need is well characterized, persistent bronchoconstriction, exacerbations, and reduced quality of life, and the regulatory pathway now established for triple therapy in asthma offers a clearer precedent for development teams pursuing similar combinations.

Breztri is currently approved for chronic obstructive pulmonary disease in 90 countries, and regulatory submissions for the asthma indication are under review in the EU, Japan, and China, each of which will require additional technical packages aligned to regional expectations.1

Ruud Dobber, executive vice president of the BioPharmaceuticals Business Unit, AstraZeneca, noted in the press release,1 "As the fastest growing fixed-dose triple-combination therapy in COPD, Breztri is already improving outcomes for people suffering with COPD, and we are proud to extend its benefits to asthma patients. The FDA's approval of Breztri in asthma demonstrates how our innovative science continues to bring new solutions for patients with respiratory diseases."

How Does AstraZeneca's Respiratory Approval Fit its Broader Immunology Pipeline?

The Breztri asthma approval arrives alongside related regulatory activity elsewhere in AstraZeneca's portfolio.2 The FDA approved a subcutaneous self-administration option for Saphnelo (anifrolumab), the company's first-in-class monoclonal antibody for systemic lupus erythematosus, via a once-weekly autoinjector called the Saphnelo Pen. That approval was supported by the Phase III TULIP-SC trial, published in Arthritis & Rheumatology in January 2026, which demonstrated statistically significant reductions in disease activity versus placebo. The back-to-back approvals, one an inhaled fixed-dose combination, the other a subcutaneous autoinjector, illustrate the continued investment in device development by one of Pharma’s largest firms.

References

1. AstraZeneca. BREZTRI approved in the US for asthma. Published April 28, 2026. Accessed April 28, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/breztri-approved-in-the-us-for-asthma.html
2. AstraZeneca. SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus. Published April 27, 2026. Accessed April 28, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/saphnelo-self-administration-approved-in-the-US.html